StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Investment analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued on Saturday. The brokerage set a “sell” rating on the stock.

Syros Pharmaceuticals Stock Down 10.9 %

NASDAQ:SYRS opened at $0.03 on Friday. The firm has a market cap of $727,147.20, a price-to-earnings ratio of -0.01 and a beta of 1.31. Syros Pharmaceuticals has a 12 month low of $0.02 and a 12 month high of $6.93. The company’s 50 day moving average is $0.14 and its 200-day moving average is $0.79.

Institutional Trading of Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. Two Sigma Securities LLC purchased a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.40% of Syros Pharmaceuticals as of its most recent SEC filing. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.